文献速递分子诊断质量管理与危急值

BD Onclarity HPV检测在丹麦SurePath筛查样本中的临床与分析性能:基于VALGENT框架的评估

Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
PubMed 文献 · J Clin Microbiol · 2020-01-28

本研究基于VALGENT框架第四期,使用丹麦宫颈筛查的998例连续样本和297例细胞学异常富集样本,评估BD Onclarity HPV检测的分析与临床性能。结果显示,其检测≥CIN2的相对敏感度为1.00(95%CI 0.97-1.04),检测2×NILM的相对特异度为1.04(95%CI 1.02-1.06),非劣效于GP-EIA(P=0.0006和P<0.0001)。SurePath样本冷藏7个月后内参CT值保持24.8不变,提示样本稳定性良好。

要点

  • Onclarity检测≥CIN2的敏感度非劣效于GP-EIA,相对敏感度1.00。
  • 检测2×NILM的特异度非劣效,相对特异度1.04。
  • SurePath样本冷藏7个月仍可保持检测有效性。

核心结论

  • BD Onclarity HPV检测在丹麦SurePath筛查样本中检测≥CIN2的敏感度和检测2×NILM的特异度均非劣效于GP-EIA。
  • Onclarity对几乎所有HPV基因型组与GP-LMNX显示良好一致性。
  • SurePath样本冷藏7个月后Onclarity内参CT值不变(24.8),样本仍为有效检测标本。

研究设计与样本

  • 基于VALGENT框架第四期,使用丹麦宫颈筛查的998例连续样本和297例细胞学异常富集样本(100例ASCUS、100例LSIL、97例HSIL)。
  • 以GP5+/6+ PCR-酶免疫分析(GP-EIA)为对照,采用非劣效性检验评估临床性能。
  • 基因型特异性性能以GP5+/6+ PCR结合Luminex基因分型(GP-LMNX)为对照进行评估。
  • 稳定性分析:SurePath等分样本冷藏7个月,以Onclarity内参作为细胞量标记。

主要发现

  • 检测≥CIN2的相对敏感度为1.00(95%CI 0.97-1.04)。
  • 检测2×NILM的相对特异度为1.04(95%CI 1.02-1.06)。
  • 敏感度非劣效性检验P=0.0006,特异度非劣效性检验P<0.0001。
  • Onclarity对几乎所有HPV基因型组与GP-LMNX显示良好一致性。
  • 冷藏7个月后Onclarity内参CT值在两次运行中均为24.8。

关键数值与推荐

  • Onclarity检测≥CIN2的相对敏感度为1.00(95%CI 0.97-1.04),非劣效于GP-EIA(P=0.0006)。
  • Onclarity检测2×NILM的相对特异度为1.04(95%CI 1.02-1.06),非劣效于GP-EIA(P<0.0001)。
  • SurePath样本冷藏7个月后Onclarity内参CT值为24.8,与首次运行相同。

临床怎么用

  • Onclarity可用于丹麦SurePath宫颈筛查样本的HPV检测,其临床性能非劣效于GP-EIA。
  • SurePath样本冷藏7个月仍可保持检测有效性,支持样本的短期储存与运输。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Validation of HPV Genotyping Tests (VALGENT) framework is an international cooperation designed to evaluate human papillomavirus (HPV) assays with genotyping capabilities. Here, we assessed the performance of the BD Onclarity assay using Danish SurePath cervical screening samples collected under the fourth VALGENT installment, consisting of 998 consecutive samples from a screening population and 297 enriched samples with abnormal cytology (100 with atypical squamous cells of undetermined significance [ASCUS], 100 with low-grade squamous intraepithelial lesions [LSIL], and 97 with high-grade squamous intraepithelial lesions [HSIL]). The Onclarity assay detects six HPV genotypes individually (genotypes 16, 18, 31, 45, 51, and 52) and eight genotypes in three bulks (genotypes 33 and 58; genotypes 56, 59, and 66; and genotypes 35, 39, and 68). The clinical performance of the Onclarity assay for the detection of cervical intraepithelial neoplasia of grade 2 or worse (≥CIN2) and of two consecutive cytology outcomes negative for intraepithelial lesion or malignancy (2×NILM) was assessed relative to that of the GP5+/6+ PCR-enzyme immunoassay (GP-EIA) by a noninferiority test. The relative sensitivity for ≥CIN2 was 1.00 (95% confidence interval [CI], 0.97 to 1.04), and the relative specificity for 2×NILM was 1.04 (95% CI, 1.02 to 1.06). The Onclarity assay was found to be noninferior to the GP-EIA in terms of both sensitivity (P = 0.0006) and specificity (P < 0.0001). The type-specific performance of the Onclarity assay was also assessed, using the GP5+/6+ PCR with Luminex genotyping (GP-LMNX) as the comparator. The Onclarity assay showed good concordance for almost all HPV genotype groups. A stability analysis of SurePath samples was also performed, where a SurePath aliquot was stored refrigerated for 7 months and the internal control of the Onclarity assay was used as a marker for cellularity. The threshold cycle (CT ) value was the same (24.8) in the first and second Onclarity runs, showing that a SurePath sample can be stored refrigerated for 7 months and still remain a valid test specimen.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Bonde JH, Pedersen H, Quint W, et al. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework. J Clin Microbiol. 2020. PMID: 31723012. doi:10.1128/JCM.01518-19

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。